About
This medication combines the therapeutic actions of Remogliflozin and Metformin, offering a comprehensive approach to managing type 2 diabetes mellitus. Remogliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, which works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and a subsequent reduction in blood glucose levels. This mechanism is independent of insulin secretion. Metformin, a biguanide, acts primarily by decreasing glucose production in the liver, reducing glucose absorption from the intestines, and improving insulin sensitivity in peripheral tissues, thereby enhancing glucose uptake and utilization. The synergistic effect of these two agents addresses multiple pathophysiological defects in type 2 diabetes, leading to significant improvements in glycemic control, including reductions in fasting and postprandial glucose levels and HbA1c. This combination is particularly beneficial for patients who require more intensive glycemic management or who have not achieved adequate control with monotherapy.
Uses
- Management of type 2 diabetes mellitus in adults.
- Improvement of glycemic control as an adjunct to diet and exercise.
- Reduction of elevated fasting and postprandial blood glucose levels.
- Lowering of HbA1c levels to achieve target glycemic goals.
Directions For Use
Take orally, usually once or twice daily, with meals as directed by your physician. Swallow the tablet whole with water.
Benefits
- Significant reduction in blood glucose levels.
- Improved long-term glycemic control (HbA1c).
- Potential for modest weight reduction.
- May offer cardiovascular protective effects.
- May provide renal protective benefits.
- Comprehensive management through multiple mechanisms of action.
Side Effects
- Genital mycotic infections
- Urinary tract infections (UTIs)
- Increased urination (polyuria)
- Thirst/dehydration
- Nausea
- Diarrhea
- Abdominal discomfort
- Metallic taste
- Headache
- Dizziness
- Hypoglycemia (especially with other antidiabetic agents)
- Rarely, lactic acidosis or diabetic ketoacidosis
Safety Measures
- Alcohol - Avoid excessive alcohol consumption, as it can increase the risk of lactic acidosis (due to Metformin) and may exacerbate dehydration associated with SGLT2 inhibitors.
- Pregnancy - Generally not recommended during pregnancy. Consult your doctor, as the risks and benefits need to be carefully weighed.
- Breastfeeding - Not recommended during breastfeeding due to potential excretion into breast milk and unknown effects on the infant. Consult your doctor.
- Liver - Use with caution in patients with liver impairment. Metformin is contraindicated in severe hepatic dysfunction due to increased risk of lactic acidosis.
- Kidney - Dose adjustment is required based on renal function. Contraindicated in severe renal impairment (eGFR below certain thresholds) for both Metformin and SGLT2 inhibitors.
- Lung - Generally safe for use in patients with stable lung conditions, but severe respiratory illness could be a risk factor for lactic acidosis with Metformin.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!